Markets › United States › NYSE › EBS

Emergent BioSolutions Inc

NYSE:EBSHealthcareCBOEFTSE:MRUTNASDAQ:NQUSSG

$6.36−0.31%At closeAt close · Tue 20 Oct · ≈ AED 23.36 · Market cap $326.1M · Next earnings Wed 28 Oct

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	54.7%	44.7%	42.3%	34.3%	36.0%	47.2%	—	—
Operating margin	27.8%	19.2%	−15.2%	−69.2%	−10.4%	14.8%	14.8%	+0.0 pts
Net margin	19.4%	12.4%	−18.9%	−72.5%	−18.3%	7.1%	7.1%	+0.0 pts
EBITDA margin	38.6%	28.4%	1.4%	−4.5%	5.1%	32.4%	—	—
Return on equity	21.1%	13.6%	−15.2%	−117.1%	−39.5%	10.1%	10.1%	+0.0 pts
Return on assets	10.6%	7.4%	−6.7%	−41.7%	−13.7%	4.0%	4.0%	+0.0 pts
Return on capital employed	17.5%	13.2%	−8.8%	−62.0%	−8.9%	9.3%	—	—
Debt / equity	0.6×	0.5×	1.0×	1.3×	1.4×	1.1×	1.1×	+0.0%
Debt / assets	32.0%	29.4%	45.0%	47.2%	48.7%	43.4%	—	—
Interest coverage	14.0×	9.9×	−4.6×	−8.3×	−1.5×	1.9×	—	—
Current ratio	3.1×	3.4×	1.0×	1.0×	3.7×	5.0×	5.0×	+0.0%
Quick ratio	2.3×	2.5×	0.7×	0.5×	1.8×	2.4×	—	—
Cash ratio	1.6×	1.5×	0.5×	0.2×	0.6×	1.6×	1.6×	+0.0%
Asset turnover	0.5×	0.6×	0.4×	0.6×	0.8×	0.6×	—	—
Inventory turnover	2.3×	2.8×	1.8×	2.1×	2.1×	1.1×	—	—
Receivables turnover	6.8×	6.4×	7.0×	5.5×	6.8×	8.8×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—